Navigation Links
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
Date:3/30/2008

h heart attack because studies have reported conflicting results on the benefits of drug-eluting stents in this group of patients and have raised concerns over the risk of blood clotting inside the stent, or stent thrombosis. The new study has certain design advantages over previous studies, specifically its size and an enrollment and follow-up protocol that more closely reflects everyday clinical practice.

As for tirofiban and abciximab, both are in a class of medications known as glycoprotein 2b/3a inhibitors and prevent blood clotting by blocking hyperactivation of platelets. Tirofiban is an attractive alternative for several reasons: It is shorter-acting and is cleared from the body more readily than abciximab, it is less likely to cause a dangerous drop in the number of platelets in the blood, and it is far less expensive. However, previous studies have been too small or have used too low a dose of tirofiban to reach a definitive conclusion about which medication is better, Dr. Valgimigli said.

The new study, which involved 16 medical centers, enrolled 745 patients who were set to undergo PCI for STEMI. Patients were randomly assigned to an infusion of abciximab or high-dose tirofiban (25 microgram/kg) and, in a second round of randomization, to treatment with either uncoated or sirolimus-eluting stents.

To judge the effectiveness of tirofiban and abciximab, researchers examined electrocardiograms -- 722 of which were interpretable -- to determine the proportion of patients with at least a 50 percent return of the elevated "ST-segment" to its normal baseline. The results were equivalent in the two groups (83.6 percent in the abciximab group vs. 85.3 percent in the tirofiban group). In addition, there was no significant difference in the rate of major adverse cardiac events (MACE) -- a combination of death, repeat heart attack, and repeat procedure to open the treated coronary artery -- in the two groups: 4.8 percent vs. 4.5 percent, respect
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
7. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
10. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
...  The Centers for Disease Control and Prevention (CDC) has ... as many people as car accidents.  Drug diversion is ... as the U.S. House of Representatives Energy and Commerce ... – "Prescription Drug Diversion: Combating the Scourge" ...
... SYDNEY, March 1, 2012  In a single bound, Nepean ... radiation therapy for its prostate cancer cases to a ... Arc Therapy), a technique that is even quicker with ... NCCC physicians treated their first patient with prostate cancer ...
Cached Medicine Technology:Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 2Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 3
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... of all lung cancers are small cell lung ... resistance to chemotherapy. However, researchers at Virginia Commonwealth ... into the mechanisms leading to this resistance that ... work primarily by mediating B-cell lymphoma 2 (Bcl-2) ... death. Depending on their function, this family of ...
(Date:4/22/2014)... The International Communication Association will hold its ... The theme of the 2014 conference will explore ... and digital society. , Featuring over 2,300 academic ... Communication scholars representing over 40 countries, the ICA ... in the world. This year,s conference features sessions ...
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
Breaking Medicine News(10 mins):Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:Neuroimaging: Live from inside the cell 2
... effect on quality of life. New invasive procedures, such ... stimulation, may help patients with chronic refractory headache. This ... and co-authors from the Department of Neurology at the ... Deutsches rzteblatt International (Dtsch Arztebl Int 2011; ...
... Aug. 24 (HealthDay News) -- Exclusive breast-feeding of infants ... against developing the itchy skin disorder known as eczema ... an infant receives only breast milk, with no additional ... Exclusive breast-feeding up to 6 months of age is ...
... in the UK, US and Canada are undermining tobacco prevention ... report by public health researchers says. The paper, published in ... films with tobacco imagery should be ineligible for public funding ... public health goals. Earlier research shows that young people ...
... Reporter , TUESDAY, Aug. 23 (HealthDay News) -- From ... in what,s been dubbed the "mancession" are redefining their ... working partners, a small study suggests. University of ... interviews of 19 recently unemployed men. She and her ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) ... to treat psoriasis -- an autoimmune disorder triggering itchy, ... linked to higher heart risks. But, the study ... makers impeded their ability to assess potential dangers noted ...
... , CHAMPAIGN, Ill. Assembling chemicals can be like ... developed a way of fitting the pieces together to ... and promising antioxidant. Led by chemistry professor Martin ... of the chemistry journal Angewandte Chemie . ...
Cached Medicine News:Health News:Breast-Feeding Won't Prevent Kids' Eczema, Researchers Say 2Health News:Government subsidies to the US film industry promote youth smoking, argue researchers 2Health News:In Tough Times, Jobless Men Embrace Housework 2Health News:In Tough Times, Jobless Men Embrace Housework 3Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:A new set of building blocks for simple synthesis of complex molecules 2
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
The uncemented hip joint prosthesis system...
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: